Article: Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis

Ethical considerations are inexorably intertwined with the conduct of clinical research. As a result of progress in immunology and biotechnology, several potent novel therapeutics have recently emerged for the treatment of patients with various immunologically driven systemic inflammatory conditions, including psoriasis and psoriatic arthritis. Because of these developments, there is a need to continually assess the design of current and future research studies so that they may be conducted in the optimal and most ethical manner.

Citing Articles

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Mason K, Barker J, Smith C, Hampton P, Lunt M, Mcelhone K JAMA Dermatol. 2018; 154(5):581-588.

PMID: 29590279 PMC: 5876819. DOI: 10.1001/jamadermatol.2018.0183.

A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis.

Finamor D, Sinigaglia-Coimbra R, Neves L, Gutierrez M, Silva J, Torres L Dermatoendocrinol. 2014; 5(1):222-34.

PMID: 24494059 PMC: 3897595. DOI: 10.4161/derm.24808.

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

Kavanaugh A, Antoni C, Gladman D, Wassenberg S, Zhou B, Beutler A Ann Rheum Dis. 2006; 65(8):1038-43.

PMID: 16439444 PMC: 1798249. DOI: 10.1136/ard.2005.045658.

References

1.

Bodenheimer T . Uneasy alliance--clinical investigators and the pharmaceutical industry. N Engl J Med. 2000; 342(20):1539-44. DOI: 10.1056/NEJM200005183422024. View

2.

Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett C, Adams J . The uncertainty principle and industry-sponsored research. Lancet. 2000; 356(9230):635-8. DOI: 10.1016/S0140-6736(00)02605-2. View

3.

Montori V, Smieja M, Guyatt G . Publication bias: a brief review for clinicians. Mayo Clin Proc. 2000; 75(12):1284-8. DOI: 10.4065/75.12.1284. View

4.

Kahn J, Mastroianni A . Moving from compliance to conscience: why we can and should improve on the ethics of clinical research. Arch Intern Med. 2001; 161(7):925-8. DOI: 10.1001/archinte.161.7.925. View

5.

Shapiro H, Meslin E . Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med. 2001; 345(2):139-42. DOI: 10.1056/NEJM200107123450212. View

6.

Hill A . Medical ethics and controlled trials. Br Med J. 1963; 1(5337):1043-9. PMC: 2122975. DOI: 10.1136/bmj.1.5337.1043. View

7.

Montaner J, OShaughnessy M, Schechter M . Industry-sponsored clinical research: a double-edged sword. Lancet. 2001; 358(9296):1893-5. DOI: 10.1016/S0140-6736(01)06891-X. View

8.

Lewis J, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B . Placebo-controlled trials and the Declaration of Helsinki. Lancet. 2002; 359(9314):1337-40. DOI: 10.1016/S0140-6736(02)08277-6. View

9.

Rothman K, Michels K . The continuing unethical use of placebo controls. N Engl J Med. 1994; 331(6):394-8. DOI: 10.1056/NEJM199408113310611. View

10.

Kleijnen J, de Craen A, van Everdingen J, Krol L . Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet. 1994; 344(8933):1347-9. DOI: 10.1016/s0140-6736(94)90699-8. View

11.

Stein C, Pincus T . Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet. 1999; 353(9150):400-3. DOI: 10.1016/S0140-6736(98)01373-7. View

12.

Forster H, Emanuel E, Grady C . The 2000 revision of the Declaration of Helsinki: a step forward or more confusion?. Lancet. 2001; 358(9291):1449-53. DOI: 10.1016/S0140-6736(01)06534-5. View

Ethical and Practical Issues in Conducting Clinical Trials in Psoriasis and Psoriatic Arthritis